Back

Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy

29 June 2021 (08:22 - 08:33)
Organised by:
Congress Presentation Part of: Young Investigator Award: clinical research Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Rene Rettl

Medical University of Vienna, Vienna (Austria)

3 More presentations in this session

Presentation thumbnail
Effect of SGLT2 inhibitors on diastolic function in patients with non-obstructive hypertrophic cardiomyopathy
Doctor M. Subramanian (Hyderabad, IN)
Abstract Slides Video
Presentation thumbnail
Efficacy of additional medical therapies in patients with heart failure, a reduced ejection fraction and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis
Doctor V. De Marzo (Genoa, IT)
Abstract Slides Video
Presentation thumbnail
Target dose of heart failure medications is associated with better mortality/morbidity: data from the Swedish Heart Failure Registry
Mr D. Rodolico (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award: clinical research
Video

The Event

Event poster

Heart Failure 2021

29 June 2021 08:22 CET
You may be interested in
thumbnail
Congress Presentation
Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy
thumbnail
Congress Presentation
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension
thumbnail
Congress Presentation
Relationship between changes in renal function after acute phase of tafamidis administration and left ventricular diastolic function at mid-term follow-up in transthyretin cardiac amyloidosis

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources